Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Jiangsu Hengrui Pharmaceutical Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multi-center, observational study in patients with Immune Thrombocytopenia (ITP) or aplastic anemia(AA) designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to the knowledge base regarding the use of hetrombopag in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving hetrombopag for the treatment of ITP/AA
This is a multi-center, observational study in patients with ITP/AA designed to describe the real-world safety and effectiveness of hetrombopag and assess the patterns of drug utilization to add to the knowledge base regarding the use of hetrombopag in routine medical practice.
Patients eligible for participation will, as part of their routine medical care, be receiving hetrombopag for the treatment of ITP/AA
The scope of the study is to collect both retrospective and prospective data. The main part of the study will be prospective collecting data on usage, effectiveness, safety and patient-reported outcomes whereas the retrospective part will consist of collection of information on previous treatments, reason for treatment switch and, if applicable, hetrombopag treatment prior to enrollment. The retrospective data collection will be based on the information available in the patient's medical records. Data will be collected for up to 12 months prior to hetrombopag treatment start.
Prospective data will be collected at routine clinical visits throughout the study. Patients will be followed for 24 months and will be enrolled until their first scheduled visit after 24 months of enrollment, or until early termination, whichever occurs first.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Full-analysis set (FAS) | The FAS includes all enrolled patients. The FAS will be used for all analyses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| hetrombopag | Drug | According to prescription |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | Information will be collected via reports from the Investigators based on the patient's medical records and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 | Data will be collected for all routine visits completed during the study period no more than 24 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Number and proportion of patients achieving hematologic response after 3/6/12/24 months treatment | Laboratory measures of CBC will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts and other hematologic assessments will be based on local laboratory results. | Data will be collected for all routine visits completed during the study period which is no more than 24 months. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The Investigators will attempt to consecutively enroll all eligible patients who present for a routine clinical visit or during a routine visit where the patient is started or continued on hetrombopag treatment
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | 430022 | China |
Not provided
Not provided
Not provided
Not provided
| The maximum continuous duration and total duration of response | Hematologic assessments will be based on local laboratory results | Data will be collected for all routine visits completed during the study period which is no more than 24 months. |
| Number and proportion of patients requiring rescue medication. | Information will be collected via the patient's medical records. | Data will be collected for all routine visits completed during the study period which is no more than 24 months. |
| Change from enrollment in the 36-Item Short Form Survey (SF-36) | SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting. | Data will be collected for all routine visits completed during the study period which is no more than 24 months. |
| Change from enrollment in the use of concomitant ITP/AA medications throughout the study | Information will be collected via the patient's medical records. | Data will be collected for all routine visits completed during the study period which is no more than 24 months. |
| Number and proportion of patients achieving a sustained remission off-treatment (SROT) after discontinuation of hetrombopag | The proportion of responders that were able to taper and discontinue hetrombopag maintaining the response during a period of observation of at least six months. | Data will be collected for all routine visits completed during the study period which is no more than 24 months. |
| ID | Term |
|---|---|
| D016553 | Purpura, Thrombocytopenic, Idiopathic |
| D000741 | Anemia, Aplastic |
| ID | Term |
|---|---|
| D011696 | Purpura, Thrombocytopenic |
| D011693 | Purpura |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D057049 | Thrombotic Microangiopathies |
| D013921 | Thrombocytopenia |
| D001791 | Blood Platelet Disorders |
| D000095542 | Cytopenia |
| D006474 | Hemorrhagic Disorders |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |
| D000740 | Anemia |
| D000080983 | Bone Marrow Failure Disorders |
| D001855 | Bone Marrow Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000614661 | hetrombopag |
Not provided
Not provided
Not provided